TABLE 2.
Ongoing clinical trials on vaccine development
| Company | Technology | Stage | Expected timeline | References |
|---|---|---|---|---|
| Inovo pharmaceuticals | INO‐4800 DNA based | Pre‐clinical studies funded by Coalition for Epidemic Preparedness Innovations (CEPI) | Human testing in few months | 73 |
| Vir Biotechnology | anti‐coronavirus monoclonal antibodies (mAbs), CRISPR‐ based screening | Pre‐clinical | No decided timeline | 74 |
| The university of oxford | Adenovirus vector and SARS‐CoV‐2 spike protein | Phase‐1 started on 23rd April in 1100 peoples | Upto 6 mo | 75 |
| University of Queensland | Molecular clamp technology | Pre‐clinical | 6 mo‐1 y | . 76 |
| Johnson & Johnson | Adenovirus based technology | Pre‐clinical | 1 y | |
| The University of Saskatchewan's | Not known | Pre‐clinical | 3‐4 mo | |
| GeoVax and BravoVax | Modified Vaccinia Ankara (MVA) platform technology | Pre‐clinical | Not known | |
| Chinese clinical trial center ChiCTR2000030906 | Clinical trial for recombinant novel coronavirus (2019‐CoV) vaccine based on adenoviral vector | Phase‐1 clinical trail | Not known | 80 |